Bayer Makes Bid for “Trust” Amid Third Monsanto Cancer Trial

Print Email Share Tweet

Bayer AG, which bought Monsanto last summer, said Monday that it was making scientific studies available for public scrutiny in an effort to counter growing concerns about the safety of Monsanto’s flagship glyphosate-based herbicide products.

“Transparency is a catalyst for trust, so more transparency is a good thing for consumers, policymakers and businesses, Liam Condon, president of Bayer’s crop science division, said in a statement. Safety, he said, is the company’s top priority.

The comments come as pressure is mounting on Bayer management as roughly 11,000 people are suing Monsanto alleging glyphosate-based herbicides such as Roundup cause non-Hodgkin lymphoma, and Monsanto has hidden the risks and manipulated the scientific record. The first Roundup cancer trial resulted in a jury verdict of $289 million in damages against Monsanto, though a judge later lowered that to $78 million. The second such trial ended last month with a jury verdict of $80.2 million against Monsanto. The third trial is now underway.

Last week U.S. District Judge Vince Chhabria told Bayer attorneys and plaintiffs’ attorneys that he would like the parties to enter into mediation to discuss a possible settlement. He vacated a fourth trial set to begin in May.

Monsanto and Bayer deny the allegations and say the weight of science supports the safety of glyphosate herbicides. They also deny claims that company scientists ghost-wrote seemingly independent scientific papers and otherwise manipulated the scientific record.

“By making our detailed scientific safety data available, we encourage anyone interested to see for themselves how comprehensive our approach to safety is. We embrace the opportunity to engage in dialogue so we can build more trust in sound science,” said Condon.

The company said it was providing access to 107 Bayer-owned glyphosate safety study reports that were submitted to the European Food Safety Authority as part of the substance authorization process in the European Union. The studies are accessible on Bayer’s transparency platform.

The news from Bayer comes ahead of an April 26 shareholders meeting in which some investors are calling for the head of Bayer CEO Werner Baumann for leading the company into the Monsanto acquisition. Monsanto’s top management walked away with millions of dollars in exit packages just before the first Roundup cancer trial, leaving Bayer holding the bag for the litigation losses and the bad publicity. Since last summer, the company has seen an exodus of customers as retailers, cities, school districts and others say they are backing away from the Monsanto herbicides.

As Bayer focuses on its messaging outside the court room, epidemiologist Beate Ritz, professor at the University of California Los Angeles School of Public Health, is due to take the stand today in Pilliod v. Monsanto,  the third Roundup cancer trial. Ritz has testified in the two prior trials that her analysis of several scientific studies shows that  there is a “credible link” between glyphosate-based herbicides such as Monsanto’s Roundup and non-Hodgkin’s lymphoma.

The current case was brought by Alva and Alberta Pilliod, a married couple who both have non-Hodgkin lymphoma they allege is due to years of Roundup use.

Following Ritz will be testimony from Dennis Weisenburger, a pathologist specializing in studying the causes of non-Hodgkin lymphoma. Weisenburger testified in the Edwin Hardeman v. Monsanto trial that Roundup is a “substantial cause” of cancer in people who are exposed.

Meanwhile, plaintiffs’ attorneys continue to worry about what they believe to be “geofencing” by Monsanto.   Geofencing is a popular advertising technique that delivers specific messaging/content to anyone within a specific geographic area designated by the company or group paying for the ad. The area can be very small, a mile radius around a specific address, for instance.  Anyone within that designated area using an app on a smart phone – such as a weather app or a game – would then be delivered the ad. Targeted individuals don’t have to be searching for information; it just appears on their smart phone.

Plaintiffs’ attorneys raised the issue in the Hardeman case, and had concerns that Monsanto was pushing messaging to jurors through geofencing in the first Roundup cancer trial, which was brought by groundskeeper Dewayne “Lee” Johnson.

In the Pilliod case, the issue was discussed Thursday in court as the plaintiffs attorneys sought a judicial order to prohibit Monsanto from the tactic, but the judge was skeptical and declined to issue such an order.

Here is part of the exchange. All can be seen in the trial transcript. 

PLAINTIFFS’ ATTORNEY BRENT WISNER:  Your Honor, I think there’s one — and I get your point. I think just to clarify one procedural factual thing. Right? If I were to walk over to a juror personally and say to you, “Hey, Juror Number 3, Monsanto’s stuff causes cancer and all these studies show it,” I mean, that would be a mistrial. Instantaneously. That’s jury tampering. Right? Now if they do that same thing — if I did the same thing by targeting every person’s phone in this courtroom or every single person’s phone in this courthouse and pushing that information, that same message to them on their phone — and what happens is -­  I don’t know if you use your phone for this kind of purposes, but, for example, when I look at my ESPN app and I’m looking at the scores for the UCLA water polo team, or whatever, you know, there’s little ads that pop up.

THE COURT: Sure.

MR. WISNER: And those ads are saying “Federal judge says Roundup is safe.” That’s the kind of stuff
we’re seeing. We saw this happening with quite intensity in the Johnson trial. Numerous jurors during voir dire mentioned that they were having these things pushed on them as soon as they walked in the building. And so whether or not Monsanto is or is not doing that, I think that if they are, that should be
prohibited. That’s not really a point of First Amendment. That is now clearly targeting people that
they know they can’t speak to.

THE COURT: And you’re asking me to assign a subjective intent that I don’t know exists and it’s
still prior restraint. I mean, technology has taken us places probably we never thought it would go… I guess if I were picking sides, I might believe that. But I can’t pick sides.

Who Is Paying for Monsanto’s Crimes? We Are

Print Email Share Tweet

This article was originally published in The Guardian.

By Carey Gillam

The chickens are coming home to roost, as they say in farm country.

For the second time in less than eight months a US jury has found that decades of scientific evidence demonstrates a clear cancer connection to Monsanto’s line of top-selling Roundup herbicides, which are used widely by consumers and farmers. Twice now jurors have additionally determined that the company’s own internal records show Monsanto has intentionally manipulated the public record to hide the cancer risks. Both juries found punitive damages were warranted because the company’s cover-up of cancer risks was so egregious.

The juries saw evidence that Monsanto has ghost-written scientific papers, tried to silence scientists, scuttled independent government testing and cozied up to regulators for favorable safety reviews of glyphosate, the active ingredient in Roundup.

Even the US district judge Vince Chhabria, who oversaw the San Francisco trial that concluded Wednesday with an $80.2m damage award, had harsh words for Monsanto. Chhabria said there were “large swaths of evidence” showing that the company’s herbicides could cause cancer. He also said there was “a great deal of evidence that Monsanto has not taken a responsible, objective approach to the safety of its product … and does not particularly care whether its product is in fact giving people cancer, focusing instead on manipulating public opinion and undermining anyone who raises genuine and legitimate concerns about the issue.”

Monsanto’s new owner, the German pharmaceutical company Bayer, asserts that the juries and judges are wrong; the evidence of a cancer risk is invalid; the evidence of bad corporate conduct is misunderstood and out of context; and that the company will ultimately prevail.

Meanwhile, Monsanto critics are celebrating the wins and counting on more as a third trial got underway this week and 11,000 additional plaintiffs await their turn. As well, a growing number of communities and businesses are backing away from use of Monsanto’s herbicides. And investors are punishing Bayer, pushing share prices to a seven-year low on Thursday.

Susquehanna Financial Group analyst Tom Claps has warned shareholders to brace for a global settlement of between $2.5bn and $4.5bn.

“We don’t believe [Monsanto] will lose every single trial, but we do believe that they could lose a significant majority,” he told the Guardian.

Following the recent courtroom victories, some have cheered the notion that Monsanto is finally being made to pay for alleged wrongdoing. But by selling to Bayer last summer for $63bn just before the Roundup cancer lawsuits started going to trial, Monsanto executives were able to walk away from the legal mess with riches. The Monsanto chairman Hugh Grant’s exit package allowed him to pocket $32m, for instance.

Amid the uproar of the courtroom scuffles, a larger issue looms: Monsanto’s push to make use of glyphosate herbicides so pervasive that traces are commonly found in our food and even our bodily fluids, is just one example of how several corporate giants are creating lasting human health and environmental woes around the world. Monsanto and its brethren have targeted farmers in particular as a critical market for their herbicides, fungicides and insecticides, and now many farmers around the world believe they cannot farm without them.

Studies show that along with promoting illness and disease in people, these pesticides pushed by Bayer and Monsanto, DowDuPont and other corporate players, are endangering wildlife, soil health, water quality and the long-term sustainability of food production. Yet regulators have allowed these corporations to combine forces, making them ever more powerful and more able to direct public policies that favor their interests.

The Massachusetts senator Elizabeth Warren this week called for taking back some of that power. She announced on Wednesday a plan to break up big agribusinesses and work against the type of corporate capture of Washington we have seen in recent years.

It’s a solid step in the right direction. But it cannot undo the suffering of cancer victims, nor easily transform a deeply contaminated landscape to create a healthier future and unleash us from the chains of a pesticide-dependent agricultural system.

And while Bayer may dole out a few billion dollars in damages, who is really being made to pay?

We all are.

Glyphosate: Cancer and Other Health Concerns

Print Email Share Tweet

Glyphosate, a synthetic herbicide patented in 1974 by the Monsanto Company and now manufactured and sold by many companies in hundreds of products, has been associated with cancer and other health concerns. Glyphosate is best known as the active ingredient in Roundup-branded herbicides, and the herbicide used with “Roundup Ready” genetically modified organisms (GMOs).

Herbicide tolerance is the most prevalent GMO trait engineered into food crops, with some 90% of corn and 94% of soybeans in the U.S. engineered to tolerate herbicides, according to USDA data. A 2017 study found that Americans’ exposure to glyphosate increased approximately 500 percent since Roundup Ready GMO crops were introduced in the U.S in 1996. Here are some key facts about glyphosate:

Most Widely Used Pesticide

According to a February 2016 study, glyphosate is the most widely used pesticide: “In the U.S., no pesticide has come remotely close to such intensive and widespread use.” Findings include:

  • Americans have applied 1.8 million tons of glyphosate since its introduction in 1974.
  • Worldwide 9.4 million tons of the chemical has been sprayed on fields – enough to spray nearly half a pound of Roundup on every cultivated acre of land in the world.
  • Globally, glyphosate use has risen almost 15-fold since Roundup Ready GMO crops were introduced.

Cancer Concerns

The scientific literature and regulatory conclusions regarding glyphosate and glyphosate-based herbicides show a mix of findings, making the safety of the herbicide a hotly debated subject:

In 2015, the World Health Organization’s International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans” after reviewing years of published and peer-reviewed scientific studies. The team of international scientists found there was a particular association between glyphosate and non-Hodgkin lymphoma.

At the time of the IARC classification, the Environmental Protection Agency (EPA) was conducting a registration review. The EPA’s Cancer Assessment Review Committee (CARC) issued a report in September 2016 concluding that glyphosate was “not likely to be carcinogenic to humans” at doses relevant to human health. In publishing the CARC report, the EPA said that it was beginning work with the National Toxicology Program to investigate the mechanisms and toxic effects of glyphosate formulations.

The agency then convened a Scientific Advisory Panel (SAP) in December 2016 to review the CARC report conclusion that glyphosate was not likely to be carcinogenic. The scientific advisory panel members were divided in their assessment of EPA’s work, with some finding the EPA erred in how it evaluated certain research. Additionally, the EPA’s Office of Research and Development determined that the agency’s Office of Pesticide Programs had not followed proper protocols in its evaluation of glyphosate. An ORD memo stated that the government scientists agreed in part with IARC and believed EPA was not properly following guidelines in coming to the conclusion that glyphosate was not likely to be carcinogenic. ORD said the evidence could be deemed to support a “likely” carcinogenic or “suggestive” evidence of carcinogenicity classification. Nevertheless the EPA issued a draft report on glyphosate in December 2017 continuing to hold that the chemical is not likely to be carcinogenic.

The European Food Safety Authority and the European Chemicals Agency have said glyphosate is not likely to be carcinogenic to humans. But a March 2017 report by environmental and consumer groups argued that regulators relied improperly on research that was directed and manipulated by the chemical industry.

The WHO/FAO Joint Meeting on Pesticide Residues determined that glyphosate was unlikely to pose a carcinogenic risk to humans from exposure through the diet, though the finding was tarnished by conflict of interest concerns after it was revealed that certain members of the group, including its chair, worked for the International Life Sciences Institute, a group funded in part by Monsanto and one of its lobbying organizations.

On March 28, 2017, the California Environmental Protection Agency’s Office of Environmental Health Hazard Assessment confirmed that it would add glyphosate to California’s Proposition 65 list of chemicals known to cause cancer. Monsanto sued to block the action but the case was dismissed. In a separate case, the court found that California could not require cancer warnings for products containing glyphosate. On June 12, 2018, the United States District Court for the Eastern District of California denied the California Attorney General’s request for the court to reconsider the decision. The court found that California could only require commercial speech that disclosed “purely factual and uncontroversial information,” and the science surrounding glyphosate carcinogenicity was not proven.

A long-running U.S. government-backed prospective cohort study of farm families in Iowa and North Carolina has not found any connections between glyphosate use and non-Hodgkin lymphoma, though researchers found that “among applicators in the highest exposure quartile, there was an increased risk of acute myeloid leukemia (AML) compared with never users…” The most recent published update to the study was made public in late 2017.

New studies in 2019 report cancer links and concerns about the validity of the EPA classification:  

  • An analysis published January 2019 argues that the U.S. EPA’s classification of glyphosate disregarded substantial scientific evidence of genotoxicity (the negative impact on a cell’s genetic material) associated with weed killing products such as Roundup.
  • A February 2019 meta-analysis of scientific studies reported a “compelling link” between glyphosate-based herbicides and non-Hodgkin lymphoma. Three of the study authors were members of the EPA’s scientific advisory panel on glyphosate who have stated publicly that the EPA failed to follow proper scientific practices in its glyphosate assessment.
  • A March 2019 study analyzed data from more than 30,000 farmers and agricultural workers from studies done in France, Norway and the U.S., and reported links between glyphosate and diffuse large B-cell lymphoma.

Cancer Lawsuits

More than 650 lawsuits against Monsanto Co. are part of multi district litigation (MDL) being overseen by Judge Vince Chhabria in U.S. District Court in San Francisco, filed by people alleging that exposure to Roundup herbicide caused them or their loved ones to develop non-Hodgkin lymphoma, and that Monsanto covered up the risks. An estimated 9,000 similar actions are pending in state courts. U.S. Right to Know is posting key documents from the litigation on our Monsanto Papers pages. See Carey Gillam’s Roundup Trial Tracker for news and tips about the ongoing legislation. 

In March 2017, the federal court judge unsealed some internal Monsanto documents that raised new questions about Monsanto’s influence on the EPA process and about the research regulators rely on. The documents suggest that Monsanto’s long-standing claims about the safety of glyphosate and Roundup do not necessarily rely on sound science as the company asserts, but on efforts to manipulate the science.

A study for the European Parliament published January 15, 2019 asserts that the EU approval of glyphosate was based on plagiarized text from Monsanto. The study found plagiarism in 50.1 percent of chapters dealing with the assessment of published studies on health risks related to glyphosate in Germany’s Federal Institute for Risk Assessment, including whole paragraphs and entire pages of plagiarized text.

See also 2018 journal articles about scientific interference:

The first trial concluded in August 2018 with the jury ruling that Monsanto’s weed killer was a substantial contributing factor in causing DeWayne “Lee” Johnson’s cancer, and ordering Monsanto to pay $289.25 million in damages, including $250 million in punitive damages. The judge in the case reduced the punitive damages to $39 million, bringing the total award to $78 million. Monsanto declared it would appeal and Johnson has cross-appealed, seeking to reinstate the jury award.

March 19, 2019 update: In a blow to Bayer, a federal journey handed a first-round victory to plaintiff Edwin Hardeman, as the six jury members found that Hardeman’s exposure to Roundup was a “substantial factor” in causing his non-Hodgkin lymphoma. The jury decision means the trial now moves into a second phase in which jurors will take up the issue of liability and damages.

Endocrine Disruption and Other Health Concerns

Some research suggests that glyphosate may be an endocrine disruptor. It has also been linked to liver disease, birth defects and reproductive problems in laboratory animals; and may kill beneficial gut bacteria and damage the DNA in human embryonic, placental and umbilical cord cells. Many scientists have raised concerns about the health risks of glyphosate. See:

Recent studies have shown adverse biological effects from low-dose exposures to glyphosate at levels to which people are routinely exposed.

  • A birth cohort study in Indiana published in 2017 – the first study of glyphosate exposure in US pregnant women using urine specimens as a direct measure of exposure – found detectable levels of glyphosate in more than 90% of the pregnant women tested and found the levels were significantly correlated with shortened pregnancy lengths.
  • A 2018 ecological and population study conducted in Argentina found high concentrations of glyphosate in the soil and dust in agricultural areas that also reported higher rates of spontaneous abortion and congenital abnormalities in children, suggesting a link between environmental exposure to glyphosate and reproductive problems. No other relevant sources of pollution were identified.
  • A 2017 study associated chronic, very low-level glyphosate exposures to non-alcoholic fatty liver disease in rats. According to the researchers, the results “imply that chronic consumption of extremely low levels of a GBH formulation (Roundup), at admissible glyphosate-equivalent concentrations, are associated with marked alterations of the liver proteome and metabolome,” the biomarkers for NAFLD.
  • A 2018 rat study conducted by the Ramazzini Institute reported that low-dose exposures to Roundup at levels considered safe significantly altered the gut microbiota in some of the rat pups. Another 2018 study reported that higher levels of glyphosate administered to mice disrupted the gut microbiota and caused anxiety and depression-like behaviors.
  • A 2018 rat study by Argentinian researchers linked low-level perinatal glyphosate exposures to impaired female reproductive performance and congenital anomalies in the next generation of offspring.

Glyphosate has also been linked by recent studies to harmful impacts on bees and monarch butterflies.

Desiccation

Some farmers use glyphosate on non-GMO crops such as wheat, barley, oats, and lentils to dry down the crop ahead of harvest in order to accelerate the harvest. This practice, known as desiccation, may be a significant source of dietary exposure to glyphosate.

Glyphosate Found in Food: U.S. Drags Its Feet on Testing

The USDA quietly dropped a plan to start testing food for residues of glyphosate in 2017. Internal agency documents obtained by U.S. Right to Know show the agency had planned to start testing over 300 samples of corn syrup for glyphosate in April 2017. But the agency killed the project before it started. The U.S. Food and Drug Administration began a limited testing program in 2016, but the effort was fraught with controversy and internal difficulties and the program was suspended in September 2016. Both agencies have programs that annually test foods for pesticide residues but both have routinely skipped testing for glyphosate.

Before the suspension, one FDA chemist found alarming levels of glyphosate in many samples of U.S. honey, levels that were technically illegal because there have been no allowable levels established for honey by the EPA. Here is a recap of news about glyphosate found in food:

Pesticides in Our Food: Where’s the Safety Data?

USDA data from 2016 shows detectable pesticide levels in 85% of more than 10,000 foods sampled, everything from mushrooms to grapes to green beans. The government says there are little to no health risks, but some scientists say there is little to no data to back up that claim. See “Chemicals on our food: When “safe” may not really be safe: Scientific scrutiny of pesticide residue in food grows; regulatory protections questioned,” by Carey Gillam (11/2018).

New Analysis Raises Questions About EPA’s Glyphosate Classification

Print Email Share Tweet

Researcher says the EPA has disregarded substantial evidence that the popular herbicide is linked to cancer

This article was originally published in Environmental Health News.

By Carey Gillam

A little more than a month ahead of a first-ever federal trial over the issue of whether or not Monsanto’s popular weed killers can cause cancer, a new analysis raises troubling questions about the U.S. Environmental Protection Agency’s (EPA) handling of pertinent science on glyphosate safety.

According to the report, which examines the opposing positions taken by the EPA and an international cancer research agency on glyphosate-based herbicides, the EPA has disregarded substantial scientific evidence of genotoxicity associated with weed killing products such as Roundup and other Monsanto brands. Genotoxicity refers to a substance’s destructive effect on a cell’s genetic material. Genotoxins can cause mutations in cells that can lead to cancer.

The EPA classifies glyphosate as not likely to be carcinogenic while the International Agency for Research on Cancer (IARC), which is part of the World Health Organization, classifies it as “probably carcinogenic.”

The paper was authored by Charles Benbrook, a former research professor who served at one time as executive director of the National Academy of Sciences board on agriculture, and was published in the journal Environmental Sciences Europe on Monday. It is based on Benbrook’s review of EPA and IARC records regarding the types and numbers of glyphosate studies each organization evaluated.

“Clearly, compared to EPA’s genotoxicity review, the IARC review is grounded on more recent, more sensitive, and more sophisticated genotoxic studies, and more accurately reflects real-world exposures,” Benbrook told EHN.

Benbrook testified as an expert witness in the first lawsuit to go to trial against Monsanto over claims its glyphosate herbicides cause cancer. The plaintiff in that case, Dewayne “Lee” Johnson, won a unanimous jury award of $289 million last year that the judge in the case cut to $78 million. Thousands of additional cancer victims have sued Monsanto and the second trial begins Feb. 25 in federal court in San Francisco. Benbrook is also expected to testify for the plaintiff in that case.

Monsanto is seeking to exclude Benbrook’s testimony at trial, saying he has no expertise in any physical science or field of medicine and no training or degree in toxicology and has never worked at the EPA or other regulatory body.

The EPA did not respond to a request for comment. The agency has maintained, however, that its review of glyphosate has been robust and thorough. Glyphosate has low toxicity for humans, and glyphosate products can be safely used by following directions on labeled products, according to the EPA.

In the new analysis, Benbrook is critical of the EPA’s scrutiny of glyphosate herbicides, noting that little weight was given to research regarding the actual formulations sold into the marketplace and used by millions of people around the world. Instead, the EPA and other regulators have mostly pointed to dozens of studies paid for by Monsanto and other companies selling glyphosate herbicides that found no cancer concerns. The EPA has given little attention to several independent research projects that have indicated the formulations can be more toxic than glyphosate alone, according to Benbrook.

Indeed, the EPA only started working in 2016—some 42 years after the first glyphosate herbicides came to market – with the U.S. National Toxicology Program to evaluate the comparative toxicity of the formulations. Early results disclosed in 2018 supported concerns about enhanced toxicity in formulations.

Several scientists, including from within the EPA’s Office of Research and Development (ORD), and from a panel of scientific experts convened by the EPA, have cited deficiencies and problems with the EPA’s decision to classify glyphosate as not likely to be carcinogenic to humans. But Benbrook’s analysis is the first to look deeply at how and why the EPA and IARC drew such divergent conclusions.

Benbrook looked at the citations for genotoxicity tests discussed in the EPA and IARC reports, both those that were published in peer-reviewed journals and the unpublished ones that were presented to the EPA by Monsanto and other companies.

Some studies looked at glyphosate alone, and/or glyphosate-based herbicide formulations and some included findings about a substance called aminomethylphosphonic acid (AMPA), which is glyphosate’s primary metabolite.

Benbrook’s analysis found that within the body of available evidence, the EPA relied on 151 studies, 115 of which showed negative results, meaning no evidence of genotoxicity, and only 36 that had positive results. IARC cited 191 studies, only 45 of which showed negative results and 146 of which showed evidence of genotoxicity.

IARC said within these studies it found “strong evidence that exposure to glyphosate or glyphosate-based formulations is genotoxic…”

Benbrook’s analysis reports that over the last three years at least 27 additional studies have been published addressing possible mechanisms of genotoxic action for glyphosate and/or formulated glyphosate-based herbicides and all but one of the 27 studies reported one or more positive result. There were 18 positives arising from DNA damage, six associated with oxidative stress, and two with other genotoxicity mechanisms, his paper states.

According to Benbrook, the EPA’s failure to focus on formulated glyphosate-based herbicides is dangerous because these formulations “account for all commercial uses and human exposures (no herbicide products contain just glyphosate).”

More research is needed on real-world exposures, Benbrook concludes.

Update: See also the editorial by the editors of Environmental Sciences Europe about the implications of Benbrook’s analysis, “Some food for thought: a short comment on Charles Benbrook’s paper“.

Carey Gillam is a journalist and author, and a public interest researcher for US Right to Know, a not-for-profit food industry research group. Follow her on Twitter at @careygillam.

Rachel Carson Environment Book Award Winner: Whitewash by Carey Gillam

Print Email Share Tweet

Carey Gillam’s “Whitewash: The Story of a Weed Killer, Cancer and the Corruption of Science (Island Press) has received rave reviews since its release last fall and has received several awards for outstanding reporting:

Hard-hitting, eye-opening narrative…A forceful argument for an agricultural regulatory environment that puts public interest above corporate profits.”  Kirkus Reviews

This is a must-read for everyone concerned about the increasing burden of toxic chemicals in water and food, the health and environmental consequences thereof, and corporate influence on government agencies.Booklist 

“Gillam expertly covers a contentious front where corporate malfeasance intersects with issues of public health and ecology.” Publishers Weekly 

“a gutsy, compelling read from beginning to end, especially for readers who enjoy the kind of hard-nosed, shoe-leather reporting that used to be the hallmark of great journalism.” Society for Environmental Journalists BookShelf

“well-documented compendium of wrongs, fraud, conflicts of interest, undue influence, and troubling forms of plain old [PR]….Some of its revelations are downright infuriating. Los Angeles Review of Books 

See also: Carey Gillam’s testimony before a joint committee of the European Parliament on 10/11/2017 and her reporting from the Daubert Hearings in the Cancer Victims Vs. Monsanto glyphosate litigation.

Book Description

It’s the pesticide on our dinner plates, a chemical so pervasive it’s in the air we breathe, our water, our soil, and even found increasingly in our own bodies. Known as Monsanto’s Roundup by consumers, and as glyphosate by scientists, the world’s most popular weed killer is used everywhere from backyard gardens to golf courses to millions of acres of farmland. For decades it’s been touted as safe enough to drink, but a growing body of evidence indicates just the opposite, with research tying the chemical to cancers and a host of other health threats.

In Whitewash, veteran journalist Carey Gillam uncovers one of the most controversial stories in the history of food and agriculture, exposing new evidence of corporate influence. Gillam introduces readers to farm families devastated by cancers which they believe are caused by the chemical, and to scientists whose reputations have been smeared for publishing research that contradicted business interests. Readers learn about the arm-twisting of regulators who signed off on the chemical, echoing company assurances of safety even as they permitted higher residues of the pesticide in food and skipped compliance tests. And, in startling detail, Gillam reveals secret industry communications that pull back the curtain on corporate efforts to manipulate public perception.

Whitewash is more than an exposé about the hazards of one chemical or even the influence of one company. It’s a story of power, politics, and the deadly consequences of putting corporate interests ahead of public safety.

http://careygillam.com/book
Publication date October 2017

Home

More Praise for Whitewash

“The book unravels a tapestry of pesticide industry tricks to manipulate the scientific truths about their products while placing profits above human health and the environment. As someone who has experienced similar actions by corporations firsthand in my work far too often, I am hopeful that Carey’s book will be a wake-up call for more transparency about the dangers surrounding many chemicals in the marketplace.” Erin Brockovich, environmental activist and author

Carey Gillam has brilliantly assembled the facts and describes how Monsanto and other agricultural chemical companies lied about their products, covered up the damaging data and corrupted government officials in order to sell their toxic products around the world.  David Schubert, Ph.D., Professor and Head of the Cellular Neurobiology Laboratory at the Salk Institute For Biological Studies

Carey Gillam is a brave warrior in the mold of Rachel Carson. She has exposed the ruthless greed and fraud which have led to the poisoning of our planet. Brian G.M. Durie, M.D. Chairman of the International Myeloma Foundation, oncology specialist and attending physician at Cedars-Sinai Medical Center

In the grand tradition of Silent Spring, Carey Gillam’s Whitewash is a powerful exposé that sheds light on a chemical that — to most of us — is both entirely invisible and yet profoundly damaging to our bodies and our environment. It is a deeply researched, entirely convincing exposé of the politics, economics and global health consequences implicit in the spread of the world’s most common herbicide. Gillam has done what all great journalists strive to do: she has made us see clearly what has long been right before our eyes. Highly recommended.  McKay Jenkins, author, Professor of English, Journalism and Environmental Humanities at the University of Delaware

SF Roundup Case Demonstrates Importance of Independence in Scientific Evidence

Print Email Share Tweet

Thisarticlewas originally publishedinSanFranciscoChronicle.

By Nathan Donley and Carey Gillam

It’s been three weeks since a San Francisco jury found that exposure to Monsanto’s Roundup herbicides contributed to former school groundskeeper Dewayne “Lee” Johnson’s terminal cancer and awarded a stunning $289 million in damages to the 46-year-old father. And during that time, we’ve seen repeated assertions from the pesticide giant and its allies that, in fact, the jury was wrong and the weed killer of choice for millions of Americans is perfectly safe.

Monsanto Vice President Scott Partridge repeated the familiar mantra: Hundreds of scientific studies, as well as reviews by regulatory agencies across the globe, including the U.S. Environmental Protection Agency, have found that glyphosate — the active ingredient in Roundup — does not cause cancer. Monsanto’s new owner, Bayer AG, went further. Bayer CEO Werner Baumann told investors that the jury was just flat-out “wrong” and that Bayer would work to ensure that sales of the weed-killing products were not interrupted. “More than 800 scientific studies and reviews” support glyphosate safety, he told investors.

Unchallenged, the carefully honed talking points sound impressive and conclusive — exactly as intended.

But in the wake of the jury’s award, many people across the United States who have been spraying the pesticide on their lawns and gardens for years doubt those reassuring words. And with good reason.

Corporate assurances of safety leave out one important word — a word that is critically important to anyone who wants to make an informed decision about the cancer risk associated with Roundup and the hundreds of other glyphosate-based herbicides on the market.

That word is “independent,” as in “independent scientific studies and reviews.”

As was laid out in the trial, there is a wealth of evidence, much of it from within Monsanto’s own internal documents, detailing how much of the research suggesting that Roundup is safe has been orchestrated and/or influenced by Monsanto and its chemical industry allies.

But truly independent research has shown that there is reason for concern. As Roundup use on U.S. farms, residential lawns and gardens has soared from roughly 40 million pounds a year in the 1990s to nearly 300 million pounds in recent years, the dangers of the chemical have been documented in numerous peer-reviewed studies.

It was those independent and peer-reviewed works that convinced the cancer research arm of the World Health Organization to determine that glyphosate is a probable human carcinogen. In the wake of that WHO finding, California added glyphosate to the state’s list of cancer-causing chemicals.

Monsanto’s response to that 2015 classification was more manipulated science. An “independent review” of glyphosate showed up in a peer-reviewed scientific journal decrying the IARC classification. The review not only was titled as being independent, but declared that no Monsanto employee had any involvement in the writing of it. Yet the company’s internal emails, turned over in discovery associated with the litigation, revealed that a Monsanto scientist in fact aggressively edited and reviewed the analysis prior to its publication.

That was but one of multiple examples detailed in the unsealed documents of similar efforts, referred to by Monsanto’s own employees as “ghostwriting.”

The EPA has sided with Monsanto over independent scientists, declaring the pesticide is not likely to cause cancer. By doing so, the agency has ignored the fact that its own Office of Research and Development expressed unease with the EPA’s handling of the glyphosate evaluation, as did a scientific advisory panel convened by the agency to peer-review the evaluation.

Perhaps not surprisingly, the trial evidence also included communications detailing what can only be described as cozy collaborations between Monsanto and certain EPA officials.

Americans deserve better from their regulators, whose priority should be to put the public’s health far before corporate profits.

Instead, it took a brave man dying of cancer and jury of 12 ordinary citizens to step up and face the challenge of taking a hard look at the scientific facts and calling for justice.

A Story Behind the Monsanto Cancer Trial — Journal Sits on Retraction

Print Email Share Tweet

What “ghostwriting” by Monsanto means, how it has influenced, and still is influencing, material found in peer-reviewed scientific journals

This article was originally published in Environmental Health News.

By Carey Gillam and Nathan Donley

Consumers and journalists around the world were stunned earlier this month when Monsanto, after being forced in a court of law for the first time to defend the safety of its popular weed killer Roundup, was found liable for the terminal cancer of California groundskeeper Dewayne Johnson.

The unanimous 12-member jury found that Mr. Johnson’s exposure to Monsanto’s weedkiller was a “substantial” contributing factor to his disease and that there was “clear and convincing” evidence that Monsanto acted with “malice or oppression” because the risks were evident and Monsanto failed to warn of those known risks.

Aside from dueling expert testimony on both sides, the jury was provided with internal company emails and work plans indicating that Monsanto had been corrupting the scientific record by ghostwriting literature asserting safety.

As the jury’s decision sets in, and thousands of additional plaintiffs who have filed similar suits wait for their day in court, it is worth taking time to understand exactly what “ghostwriting” by Monsanto means, how it has influenced, and still is influencing, material found in peer-reviewed scientific journals.

We offer this example:

When the scientific journal Critical Reviews in Toxicology (CRT) published a series of papers reviewing the carcinogenic potential of weed-killing agent glyphosate, the main ingredient in Monsanto’s Roundup, in September 2016, the findings were so significant that they were widely reported by media outlets around the world.

The papers, published in a special issue of CRT entitled “An Independent Review of the Carcinogenic Potential of Glyphosate,” directly contradicted the findings of the World Health Organization’s International Agency for Research on Cancer (IARC), which in 2015 found glyphosate to be a probable human carcinogen. The authors of the 2016 review found that the weight of evidence showed the weed killer was unlikely to pose any carcinogenic risk to people.

The findings were critical to Monsanto – the company was facing doubts by European regulators about allowing glyphosate to remain on the market. As well, Monsanto was facing a growing mass of lawsuits claiming its weed killer caused people to develop non-Hodgkin lymphoma.

Sixteen scientists from “four independent panels” signed their names to the published work, declaring to readers that their conclusions were free of Monsanto’s intervention. Underscoring the supposed independence of the work, the declaration of interest section stated: “Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel’s manuscripts prior to submission to the journal.”

It has since become evident that these papers were anything but independent. Internal Monsanto documents forced into the public spotlight through litigation show that the papers were conceptualized from the outset as a deceptive strategy for Monsanto. One of Monsanto’s top scientists not only reviewed the manuscripts but had a hand in drafting and editing them. The finished papers were aimed directly at discrediting IARC’s classification.

In one internal email, Monsanto’s chief of regulatory science, William Heydens, told the organizer of the panel: “I have gone through the entire document and indicated what I think should stay, what can go, and in a couple spots I did a little editing.”

The internal documents show that Heydens even argued over statements that he wanted included but that author John Acquavella deemed “inflammatory” and “not necessary” criticisms of IARC. Draft documents show Heydens’ edits contradicted Acquavella’s edits even though Heydens was not supposed to have even reviewed the papers. Heydens went so far as to state: “I would ignore John’s comment” and “I don’t see a reason for deleting the text that John did below.”

Other edits show Heydens attempting to control the tone of the manuscript, stating: “The deleted statement below has nothing to do with IARC criticism and should be put back in, John over-stepped the bounds here” and “I can live with deleting the text below, assuming that exposure text above … is added back in.” He also argued for putting a deleted phrase back in because it gave “clarity about IARC’s approach.” “This is not inflammatory, it is descriptive,” he wrote.

The importance of the papers to Monsanto as a tool to counter IARC’s classification of glyphosate as a probable carcinogen was laid out in a confidential document dated May 11, 2015, naming several of the scientists who could be used as authors to give the papers credibility. The internal documents speak of “ghost-writing” strategies aimed at using non-company scientists as authors to lend credibility to the findings.

When placed under oath in a deposition, Heydens acknowledged that the manuscripts were sent to him and he read “parts of some of them,” prior to their submission to the journal. He said he did not “recall” whether or not he made the 28 edits that plaintiffs’ attorneys counted in the internal records.

All of this was among the evidence presented to jurors in San Francisco Superior Court as they considered Johnson’s claims. But the evidence of ghostwriting and misconduct have far broader implications than one lawsuit.

How many ghostwritten papers declaring pesticide safety are littering the scientific literature? And given the evidence of misconduct in this instance, why are these papers still in publication? Why has there been no retraction, no clarification, no correction to the obviously deceptive disclosure?

Last August, after the documents gained media attention CRT editor Roger McClellan said the “serious accusations” deserved “careful investigation,” and he and CRT publisher Taylor & Francis would take “appropriate action.”

Shortly thereafter the Center for Biological Diversity and three other national environmental-health organizations sent a letter to CRT and Taylor & Francis detailing the ethical misconduct and formally asking for a retraction. It’s been more than a year since this investigation was begun and, despite multiple follow-up requests by the organizations, no action has been taken.

With Taylor & Francis’s own policy being to issue a retraction for misconduct “when there has been an infringement of publishing ethics,” the case for retraction couldn’t be more clear.

Monsanto’s fingerprints are all over this “independent” review, as laid out in Monsanto’s own internal documents.

Taylor & Francis must determine the standards to which it is willing to hold scientists who publish in its journals – if not for the reputation of the journals themselves, then for the sake of scientific integrity itself and the public’s right to the truth.

A Day of “Reckoning” for Monsanto

Print Email Share Tweet

Jury finds that the popular Roundup weed killer causes cancer

This article was originally published in Sierra.

By Carey Gillam

It was a blistering closing argument: In concluding the world’s first-ever court case against Monsanto Company over claims its Roundup herbicide causes cancer, attorney Brent Wisner asked jurors to deliver a message so powerful that Monsanto would have to be called to change.

“Every single cancer risk that has been found has this moment, every single one, where the science finally caught up, where they couldn’t bury it anymore,” Wisner told the jury of seven men and five women. “This is the day Monsanto is finally held accountable.” He implored them to return a verdict that said, “Monsanto, no more.” The jurors hearing the case in San Francisco Superior Court held the power to return a verdict “that actually changes the world,” Wisner told them. This trial, he said, was the company’s “day of reckoning.”

It is unclear at this point if the jury verdict—$289.25 million, which includes the staggering sum of $250 million in punitive damages—will significantly change the widespread global use of glyphosate. Still, glyphosate-based herbicides like Roundup are facing increasing questions both about their impact on human health, and what damage they might be doing to the environment.

The verdict handed down August 10 was on behalf of just one individual: school groundskeeper Dewayne “Lee” Johnson, who is dying of non-Hodgkin lymphoma (NHL) he claimed resulted from exposure to Monsanto’s herbicide. But with roughly 4,000 additional plaintiffs with similar cancer-claim lawsuits pending, Monsanto could be facing a tsunami of litigation that could persist for many years and amount to billions of dollars in damage awards to cancer victims and their families. Discovery documents obtained from within Monsanto’s once-secret files in connection with the litigation have fueled outrage at not just the evidence of harm but also of the deceptive tactics Monsanto and chemical industry allies have employed to suppress such evidence.

Shortly before the verdict, a federal judge in Brazil ruled that new products containing glyphosate could not be registered in the country and existing registrations would be suspended. And in Germany, home to Monsanto’s new parent company, Bayer AG, the environment minister called for the use of glyphosate-based herbicides to be phased out within three years.

After the San Francisco jury verdict, Italy’s deputy prime minister, Luigi Di Maio, said that there is no longer any doubt about the dangers of the herbicide, and the country needed to fight against further use of it. France’s environment minister, Nicolas Hulot, said the substance must be banned. Hulot said it was not a fight against the interest of farmers but for their benefit. Some British retailers said they were considering pulling the weed-killing products from their shelves.

Bayer shareholders have reacted with alarm to the verdict, sending shares sliding. While Monsanto has said it will appeal, and insists that it still has the science on its side, legal experts are not confident the company can succeed.

United States lawmakers and regulators have largely shrugged off the mounting evidence of harm associated with glyphosate herbicides so far. The EPA has issued a review of glyphosate safety that concludes it is not likely to cause cancer and has taken no meaningful actions to limit its use. But as the litigation expands and foreign leaders take action restricting glyphosate products, that could change.

Glyphosate is considered the world’s most widely used weed killer. Globally, approximately 1.8 billion pounds of the herbicide is used per year, 15-fold increase from the mid-1990s. In the United States, use has grown from roughly 40 million pounds to close to 300 million pounds in that same stretch, according to data compiled by agricultural economist Charles Benbrook.

Though best known as the active ingredient in Roundup and other Monsanto products, the off-patent chemical is key in many other brands sold by rival chemical companies. Monsanto engineered the rise in use of glyphosate when it introduced genetically altered glyphosate-tolerant crops in the mid-1990s, designed to withstand direct doses of the chemical.

The “Roundup Ready” cropping system made farming easier and more efficient, but as the use of glyphosate expanded, research surrounding the chemical’s impacts also grew. Researchers have documented a decline in soil health because of overuse of glyphosate, and the chemical has been tied to the declining health of important pollinators, including bees and butterflies. Weed resistance to glyphosate has prompted farmers to combine glyphosate with dicamba and 2,4-D, older herbicides also tied to human health problems. Extensive use of glyphosate leaves residues in food and water, and studies show the chemical is routinely found in human urine. It is so pervasive in the environment that U.S. government researchers have found traces in rainfall.

The ubiquitous presence of the chemical makes the evidence of ties to disease particularly worrisome. By 2015, the body of scientific evidence tying glyphosate-based herbicides to cancer was strong enough that the World Health Organization’s International Agency for Research on Cancer (IARC) declared glyphosate to be a probable human carcinogen.

That IARC classification, issued in March 2015, triggered the onslaught of litigation, including Johnson’s lawsuit. All of the lawsuits directly challenge Monsanto’s position that its herbicides are proven safe and assert that the company has spent decades hiding the cancer-causing dangers of its popular Roundup herbicide products. The evidence of deception includes ghostwriting of scientific literature that proclaimed glyphosate herbicides safe and collaborations with certain officials with the EPA to suppress scrutiny of glyphosate-herbicide toxicity.

Monsanto insists it has done nothing wrong, and Bayer officials are standing behind the subsidiary. Monsanto officials said jurors acted on emotion rather than on sound scientific evidence, and they accused Wisner of engaging in misconduct—a “punch below the belt”—by imploring jurors to become part of history with a large damage award for Johnson. They also complained about comparisons between Monsanto’s actions regarding glyphosate and the actions of tobacco industry players in protecting cigarettes, even though lead Monsanto attorney George Lombardi is known in part for also defending tobacco companies in litigation.

But in issuing punitive damages, the jury found that there was “clear and convincing evidence” that Monsanto’s officials acted with “malice or oppression” in failing to adequately warn of the risks. As defined by the court, those words translate to a determination that Monsanto’s actions were “vile, base, or contemptible” enough to be “looked down on and despised by reasonable people.”

In the days following the verdict, hundreds of potential new clients were inundating law firms with requests to be added to the litigation. Lawyers estimate there could be 10,000 or more plaintiffs in all who will ultimately file claims.

The next Roundup trial is slated to begin October 22 in St. Louis, Missouri, and involves an Arkansas man diagnosed with non-Hodgkin lymphoma after using Roundup for years. Several more are set for 2019. Lawyers for plaintiffs say they have new evidence that will be presented in the upcoming trials that is even more disturbing than the evidence seen to date.

“It’s the beginning of the end of an era for Monsanto,” said attorney Robert F. Kennedy Jr., who assisted in the Johnson case. “This sends a message . . . there are a lot of problems with this product.”